LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target Discovery
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
LifeArc®, the UK-based medical research charity, and the Milner Therapeutics Institute at the University of Cambridge, today announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases. Under this new collaborative project, cutting-edge machine learning approaches will be developed, validated and integrated into drug discovery processes to identify novel therapeutic targets, stratify patient populations, and predict efficacy of new and existing drugs.
Combining the drug discovery expertise of LifeArc with the machine-learning and bioinformatics expertise of the Milner Therapeutics Institute will facilitate the identification and selection of novel targets for drug discovery. Data generated will enhance the design of key experiments to validate and prioritise targets. Scientists involved in this project will be co-located at LifeArc and the Milner Therapeutics Institute to take full advantage of both environments.
Prof Tony Kouzarides, Director of the Milner Therapeutics Institute said: “We are delighted to be working closely with LifeArc in applying artificial intelligence and machine learning approaches to drug discovery. There is a lot of interest in these methods for the potential benefit patients. The drug discovery insight and investment from LifeArc will be important in realising this.”
Dr Justin Bryans, Executive Director, Drug Discovery at LifeArc said: "Drug discovery is a long and risky process and our collaboration with the Milner Therapeutics Institute represents a powerful way to unlock new potential approaches to help patients. We are excited about the opportunity to work at the interface of drug discovery and AI, and apply the knowledge in this field to help expedite the delivery of new treatments to patients.”
Combining the drug discovery expertise of LifeArc with the machine-learning and bioinformatics expertise of the Milner Therapeutics Institute will facilitate the identification and selection of novel targets for drug discovery. Data generated will enhance the design of key experiments to validate and prioritise targets. Scientists involved in this project will be co-located at LifeArc and the Milner Therapeutics Institute to take full advantage of both environments.
Prof Tony Kouzarides, Director of the Milner Therapeutics Institute said: “We are delighted to be working closely with LifeArc in applying artificial intelligence and machine learning approaches to drug discovery. There is a lot of interest in these methods for the potential benefit patients. The drug discovery insight and investment from LifeArc will be important in realising this.”
Dr Justin Bryans, Executive Director, Drug Discovery at LifeArc said: "Drug discovery is a long and risky process and our collaboration with the Milner Therapeutics Institute represents a powerful way to unlock new potential approaches to help patients. We are excited about the opportunity to work at the interface of drug discovery and AI, and apply the knowledge in this field to help expedite the delivery of new treatments to patients.”
